CDKN2A and renal cell carcinoma: To assess the prevalence of CDKN2A deletions in mUC, NSCLC, and RCC, we queried the Foundation Medicine clinical database, including 140,288 patient tumor samples, for the prevalence of patients with partial (one copy, CN1) or complete (zero copy, CN0) CDKN2A deletion.